๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Oncogene products represent potential targets of tumor vaccines

โœ Scribed by T. M. Tuttle

Publisher
Springer-Verlag
Year
1996
Tongue
English
Weight
141 KB
Volume
43
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Potential immunogenicity of oncogene and
Potential immunogenicity of oncogene and tumor suppressor gene products
โœ Cornelis J.M. Melief; W.Martin Kast ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 619 KB

The immunogenicity of viral oncoproteins has been established beyond doubt. Cytotoxic T lymphocytes directed against viral oncogene products can eradicate large established tumor masses. This stage has not yet been reached for cellular oncogene and tumor suppressor gene products, but T cells have be

Human C-ERBB-2 proto-oncogene product as
Human C-ERBB-2 proto-oncogene product as a target for bispecific-antibody-directed adoptive tumor immunotherapy
โœ Takashi Nishimura; Yoshihiko Nakamura; Hideo Tsukamoto; Yasuhiro Takeuchi; Yutak ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 559 KB

To develop an efficient strategy for the targeting of antitumor effector cells, we prepared bispecific antibody (BsAb) containing anti-CD3 and an anti-c-erbB-2 proto-oncogene product. The prepared BsAb specifically reacts with both c-erb6-2positive tumor cells and CD3+ CTL. Human CD4' helper/killer

Therapeutics targeting tumor immune esca
Therapeutics targeting tumor immune escape: Towards the development of new generation anticancer vaccines
โœ Simone Mocellin; Donato Nitti ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 482 KB

## Abstract Despite the evidence that immune effectors can play a significant role in controlling tumor growth under natural conditions or in response to therapeutic manipulation, it is clear that malignant cells evade immune surveillance in most cases. Considering that anticancer vaccination has r